Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate

Treating rheumatoid arthritis to target: recommendations of an international task force

(2010) J. S. Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

The Japanese experience with biologic therapies for rheumatoid arthritis

(2010) Tsutomu Takeuchi et al.   Nature Reviews Rheumatology

The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo

(2009) Joel M. Kremer et al.   ARTHRITIS AND RHEUMATISM

Interleukin-6 as a key player in systemic inflammation and joint destruction

(2009) J.E. Fonseca et al.   AUTOIMMUNITY REVIEWS

Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study

(2009) Tsutomu Takeuchi et al.   Modern Rheumatology

Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis

(2009) Ryuji Koike et al.   Modern Rheumatology

Outcome measures in inflammatory rheumatic diseases

(2009) Jaap Fransen et al.   ARTHRITIS RESEARCH & THERAPY

Randomized controlled trial design in rheumatoid arthritis: the past decade

(2009) Vibeke Strand et al.   ARTHRITIS RESEARCH & THERAPY

Golimumab, a human antibody to tumour necrosis factor   given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study

(2008) E C Keystone et al.   ANNALS OF THE RHEUMATIC DISEASES

American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis

(2008) Kenneth G. Saag et al.   ARTHRITIS AND RHEUMATISM

Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy

(2008) Norihiro Nishimoto et al.   Modern Rheumatology